GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
Thursday, GSK plc (NYSE:GSK) announced headline results of a phase 2 trial for its mRNA seasonal influenza vaccine program.
周四，葛兰素史克公司（纽约证券交易所代码：GSK）公布了其mRNA季节性流感疫苗计划2期试验的总体结果。
The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care.
该试验研究了老年人和年轻人的一系列mRNA制剂，以评估与目前的护理标准相比，哪些候选疫苗可以改善对甲型和乙型流感菌株的免疫反应。
The data demonstrated positive immune responses against influenza A and B strains compared to the current standard of care, meeting all predefined success criteria in the tested age groups of older and younger adults.
数据显示，与目前的护理标准相比，对甲型和乙型流感菌株的免疫反应呈阳性，符合老年人和年轻人测试年龄组中所有预定义的成功标准。
Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech.
另请阅读：葛兰素史克停止单纯疱疹病毒疫苗的开发，为Moderna、BioNTech等其他竞争者扫清了道路。
Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.
中期数据表明，候选疫苗在所有测试的mRNA制剂中具有可接受的安全性和反应原性。
These results build on the previous phase 2 trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile.
这些结果建立在先前的2期试验基础上，并证实了mRNA平台具有很强的总体抗体滴度，并且具有可接受的安全性。
With these results, the GSK mRNA seasonal influenza vaccine program will progress into late-stage clinical development.
有了这些结果，GsK mRNA季节性流感疫苗计划将进入后期临床开发阶段。
Vaccine candidate based on CureVac N.V.'s (NASDAQ:CVAC) proprietary second-generation mRNA backbone
基于 CureVac N.V. 的候选疫苗s（纳斯达克股票代码：CVAC）专有的第二代 mRNA 骨干
The Phase 2 study was initiated following interim data reported in April from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal influenza.
2期研究是在4月份报告了正在进行的季节性流感1/2期联合研究的2期中期数据后启动的。
In July, GSK and CureVac restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on their respective mRNA development activities.
7月，葛兰素史克和CureVac将现有的合作重组为新的许可协议，允许两家公司优先投资并专注于各自的mRNA开发活动。
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.
自2020年以来，葛兰素史克和CureVac合作开发了用于传染病的mRNA疫苗。
Price Action: GSK stock is down 0.91% at $43.37, and CVAC stock is down 1.98% at $2.97 at last check Thursday.
价格走势：周四最后一次检查时，葛兰素史克股价下跌0.91％，至43.37美元，CVAC股价下跌1.98％，至2.97美元。
- Nvidia AI Chips Headed to Saudi Arabia, US Reassesses Export Ban
- Nvidia AI 芯片运往沙特阿拉伯，美国重新评估出口禁令